• Pazopanib Hydrochloride Assay Workflows

  2026-08-21

  Build more informative cancer research experiments with Pazopanib Hydrochloride by separating pathway inhibition, growth arrest, and cell killing. This workflow connects GW786034 dose design with angiogenesis models, renal cell carcinoma treatment research, soft tissue sarcoma therapy studies, and reproducible troubleshooting.

• Luminescent ATP Detection Assay Kit for UC Research

  2026-08-20

  Connect ATP status with inflammatory and mitochondrial readouts in ulcerative colitis models using a sensitive, streamlined luminescence workflow. The assay supports cellular ATP quantification, tissue studies, and sample preservation for downstream protein analysis without harsh acid extraction.

• PPARG R212W in FPLD3: Mechanism and Rescue

  2026-08-20

  A 2026 study characterizes the PPARG p.Arg212Trp variant in a Chinese family with familial partial lipodystrophy type 3, linking reduced receptor activity to accelerated protein degradation, mitochondrial dysfunction, and impaired adipocyte metabolism. Its partial rescue by Rosiglitazone supports a mechanistically informed approach to studying ligand-responsive PPARG defects, while remaining preliminary evidence rather than a clinical treatment claim.

• Pazopanib Hydrochloride: Smarter In Vitro Assays

  2026-08-19

  Use Pazopanib Hydrochloride as a mechanistically rich test compound while separating growth inhibition from true cell killing. This workflow combines dose-response design, anti-angiogenic assay selection, and orthogonal viability measurements for more decision-ready cancer research data.

• Separating Growth Arrest from Cell Death In Vitro

  2026-08-19

  Hannah Schwartz’s dissertation shows why conventional relative-viability measurements can obscure the distinct contributions of proliferative arrest and drug-induced cell death. Its paired, time-aware framework offers a more interpretable basis for comparing anticancer responses and designing translational in vitro studies.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-08-18

  The reference study identifies ATRX loss as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that ATRX status may help guide interpretation of RTK inhibitor and temozolomide studies, although clinical translation remains unproven.

• SHC-1 Inhibition and CFTR Surface Trafficking

  2026-08-18

  A 2026 Biochemical and Biophysical Research Communications study shows that MAPK/SHC-1-dependent internalization of CFTR is conserved across airway and intestinal epithelial models, but that pharmacological responses are strongly cell-type dependent. The work identifies both a potential route to increase surface CFTR and an important limitation: SHC-1 inhibition may alter unrelated plasma-membrane proteins in CFBE cells.

• Dual SMAD and Wnt Inhibition for iPSC-RGCs

  2026-08-17

  The reference study presents a chemically defined, non-genetic strategy for directing induced pluripotent stem cells toward retinal ganglion cells through combined SMAD and canonical Wnt inhibition. Its reproducible yield and subsequent Thy-1-positive cell enrichment address a major technical barrier in glaucoma modeling and retinal regenerative research.

• Birinapant (TL32711): Reframing Apoptosis Resistance

  2026-08-17

  A translational framework for connecting MDM1–p53 biology with IAP-directed apoptosis research, using Birinapant to design more informative resistance and combination studies.

• Hematoxylin and Eosin Staining Kit Guide

  2026-08-16

  The Hematoxylin and Eosin Staining Kit provides ready-to-use hematoxylin and eosin solutions for visualizing cellular and tissue morphology in research samples. It is suitable for paraffin-embedded and frozen sections and cytological preparations, but it is not intended for diagnostic, medical, or clinical decision-making.

• Nilotinib Restores MHC-I in Colorectal Cancer

  2026-08-15

  Dong et al. show that Nilotinib, also known as AMN-107, can restore MHC-I expression in colorectal cancer cells and improve CD8+ T-cell-mediated killing. The study identifies a dual mechanism involving cGAS-STING-NF-κB-dependent MHC-I transcription and reduced PCSK9-associated MHC-I degradation, providing a preclinical rationale for combining Nilotinib with anti-PD-L1 therapy.

• Dasatinib Monohydrate: From Kinase Control to CML Insight

  2026-08-14

  Dasatinib Monohydrate (BMS-354825) is more than a potent ABL-directed compound: it is a translational probe for separating oncogenic kinase suppression from treatment-associated immune and vascular biology. This article connects imatinib-resistant BCR-ABL inhibition with emerging evidence on neutrophil extracellular traps in chronic myeloid leukemia research and outlines a disciplined strategy for validating mechanism, resistance, and translational relevance.

• Hydrazide VEGFR-2 Inhibitors: SA7 and Antiangiogenesis

  2026-08-14

  Fatale and colleagues report 53 hydrazide-based derivatives designed to inhibit VEGFR-2 and suppress angiogenesis. SA7 showed kinase inhibition comparable to sorafenib, inhibited endothelial tube formation, and reduced HCT116 xenograft growth, making it a useful lead for investigating antiangiogenic and antiproliferative mechanisms.

• Anlotinib hydrochloride Angiogenesis Assays

  2026-08-13

  Anlotinib hydrochloride enables mechanism-focused angiogenesis experiments spanning endothelial migration, tube formation, receptor phosphorylation, and ERK pathway activity. This practical guide explains how to build reproducible workflows, compare anti-angiogenic agents, and troubleshoot common assay failures in cancer research.

• Nintedanib (BIBF 1120): A Translational Test

  2026-08-13

  Nintedanib (BIBF 1120) offers a strategically useful way to interrogate VEGFR, FGFR, and PDGFR signaling across oncology and fibrosis models. This article connects its triple angiokinase mechanism with ATRX-defined glioma vulnerability, experimental design, biomarker strategy, and translational decision-making.

16792 records 1/1120 page Next 12345 下5页 Last page